Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 7/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.62 |
| ▸ | MET | P08581 | 8/20 | 0.60 |
| ▸ | KIT | P10721 | 3/20 | 0.59 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5825958 | 0.94 | PDGFRA (0.62) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5825336 | 0.93 | PDGFRA (0.59) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5826044 | 0.93 | PDGFRA (0.56) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5825584 | 0.92 | PDGFRA (0.59) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5825951 | 0.92 | PDGFRA (0.63) | PDGFRAKDRKITFGFR2PDGFRB | |
| SCHEMBL5826016 | 0.92 | PDGFRA (0.59) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5825831 | 0.91 | KDR (0.60) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5826050 | 0.91 | PDGFRA (0.59) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL5825647 | 0.91 | KDR (0.64) | PDGFRAKDRMETKITFGFR2 | |
| SCHEMBL371654 | 0.91 | PDGFRA (0.59) | PDGFRAKDRMETKITFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | claimed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1673085-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2210607-B1 | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer | EXELIXIS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2213661-B1 | c-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| EP-2213661-A1 | c-Met Modulators and Methods of Use | Exelixis Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRA 182/4885KDR 5/4885MET 2/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | PDGFRA 2234/4885KDR 3082/4885MET 2641/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | PDGFRA 182/4885KDR 5/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.